[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children
Withdrawn
- Conditions
- Brain Tumors
- Interventions
- Drug: [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical
- Registration Number
- NCT00556153
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Brief Summary
The first phase of the study will investigate if there is increased uptake of \[F-18\]FDOPA in pediatric brain tumors when compared to normal brain tissue.
- Detailed Description
The first phase of the study will investigate if there is increased uptake of \[F-18\]FDOPA in pediatric brain tumors when compared to normal brain tissue. Tne subjects between ages 5 and 17 years will be studies, to determine if there is increased uptake of \[F-18\]FDOPA in pediatric brain tumors when compared to normal brain tissue. Drug safety will also be monitored.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Documented brain tumor at diagnosis or relapse, including high grade glioma, low grade glioma, medulloblastoma including PNET, optic pathway glioma, brainstem glioma, ependymoma.
Exclusion Criteria
- Pregnancy
- Requirement for sedation
- Lack of informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Phase I [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical Children, ages 5-15 years with brain tumors
- Primary Outcome Measures
Name Time Method Increased uptake of [F-18]FDOPA in pediatric brain tumors compared to contralateral normal brain tissue as measured by standardized uptake value and tumor/non-tumor uptake ratios 15-30 minutes after IV administration
- Secondary Outcome Measures
Name Time Method